Ahmad Z, et al. - Researchers report the results from to phase 1 studies wherein the impact of an angiopoietin-like protein 3 (ANGPTL3) inhibitor, evinacumab, in hypertriglyceridemic subjects was investigated. Subjects with triglyceride levels over 150 but equivalent to or less than 450 mg/dL and LDL-C levels of 100 mg/dL or more (n=83 for single ascending dose study [SAD]; n=56 for multiple ascending dose study [MAD]) were randomly assigned in a 3:1 matter to evinacumab:placebo. Incidence and severity of treatment-emergent adverse events were the primary outcomes. According to findings, evinacumab demonstrated good tolerability in subjects. Furthermore, the alterations in lipid were similar to those observed with ANGPTL3 loss-of-function mutations. Because of the link of the latter with attenuated cardiovascular risk, improved clinical outcomes may be achieved by ANGPTL3 inhibition.